MarketCap
Facebook
X
Telegram
Calliditas Therapeutics AB (publ) Financial Ratios 2023-2011 | CALT
Brief overview of Calliditas Therapeutics AB (publ)'s financial ratios
This overview follows the five latest available observations from 2018 through 2023.
Key multiples at the end of the period are EV/EBITDA 2.61x (median 3.8x), P/B 0.69x (median 1.04x). The current ratio basket stands about 32.6% below the five-year comparison base. Earnings and risk trends should explain the discount.
Returns on assets and capital are represented by ROE -53.8%, ROA -25.1%, ROCE -33.4%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.
What the ratios show
Calliditas Therapeutics AB (publ)'s multiples look low against history, but fundamental returns do not yet provide convincing support.
Annual Financial Ratios Calliditas Therapeutics AB (publ)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
- | - | -2.0 | -2.9 | - | - | -10.6 | - | - | - | - | - | - |
P/S |
- | - | - | 1441.2 | - | - | - | - | - | - | - | - | - |
EPS |
-8.7 | -7.8 | -9.8 | -9.7 | -0.9 | -5.1 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
-974 M | -1.25 B | 48.1 M | 513 M | -696 M | -616 M | 135 M | 41.5 M | 10 M | - | - | - | - |
EBITDA per Share |
-6.95 | -7.96 | -10.3 | -8.46 | -0.76 | -5.11 | -2.55 | - | - | - | - | - | - |
EV/EBITDA |
2.6 | 3.0 | -0.1 | -1.4 | 24.9 | 4.6 | -0.6 | - | - | - | - | - | - |
PEG |
- | - | - | 0.01 | - | - | 0.2 | - | - | - | - | - | - |
P/B |
- | - | 0.7 | 1.0 | - | - | 27.6 | - | - | - | - | - | - |
P/CF |
- | - | -2.2 | -4.1 | - | - | -1.6 | - | - | - | - | - | - |
ROE % |
- | -53.80 | -50.54 | -34.75 | -4.13 | -21.36 | -261.62 | - | - | - | - | - | - |
ROA % |
-25.07 | -21.11 | -34.90 | -29.82 | -3.85 | -20.36 | -139.34 | - | - | - | - | - | - |
ROCE % |
-33.39 | -25.92 | -39.60 | -27.96 | -3.54 | -21.43 | -255.17 | - | - | - | - | - | - |
Current Ratio |
- | - | - | 5.9 | 14.8 | 21.4 | 2.1 | - | - | - | - | - | - |
All numbers in SEK currency
Quarterly Financial Ratios Calliditas Therapeutics AB (publ)
| 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.88 | -8.69 | -1.71 | -7.78 | - | - | - | -9.84 | - | - | - | -9.66 | - | - | - | -0.88 | - | - | - | -5.09 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | -6.95 | - | -7.96 | - | - | -3.98 | -10.3 | - | -3.19 | -3.02 | -8.46 | - | -1.63 | - | -0.76 | - | - | - | -5.11 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-140.26 | -95.80 | -146.33 | -145.03 | -91.23 | -91.23 | -103.03 | -114.01 | -63.48 | -67.78 | -54.99 | -64.54 | -29.80 | -4.30 | - | -4.13 | - | - | - | -21.36 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-54.28 | -66.96 | -76.79 | -85.13 | -64.02 | -64.02 | -73.91 | -88.33 | -53.43 | -57.55 | -47.69 | -29.82 | - | -4.12 | - | -3.85 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-67.00 | -82.31 | -88.52 | -98.16 | -72.24 | -72.24 | -84.54 | -94.80 | -55.20 | -59.86 | -48.45 | -57.59 | -29.63 | -4.66 | - | -3.54 | - | - | - | -21.43 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in SEK currency
Multiples are an important financial analysis tool for the company Calliditas Therapeutics AB (publ), allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Irlanda
Canada
France
China
